Takeda announced that the FDA has approved the supplemental New Drug Application (sNDA) for Iclusig (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
Several studies detected abnormal mi-RNAs expression levels in childhood Acute Lymphoblastic Leukemia (ALL) with potential diagnostic value.
Treatment of adult acute lymphoblastic leukemia (ALL) has largely relied on cytotoxic chemotherapy agents borrowed from successful treatment regimens of pediatric ALL.
Amgen announced that data from a multicenter, randomized Phase III study evaluating the efficacy, safety and tolerability of Blincyto (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published in The Journal of the American Medical Association (JAMA).
Jazz Pharmaceuticals plc announced that the European Commission (EC) has granted marketing authorization for Enrylaze (JZP 458; a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase
Advances in genomic research and risk-directed therapy have led to improvements in the long-term survival and quality of life outcomes of patients with childhood acute lymphoblastic leukaemia (ALL)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions...
“A new frontier in cancer treatment” for acute lymphoblastic leukemia (ALL).
Kite, a Gilead Company announced that the European Commission (EC) has approved its CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL).